Finally, our drug sensitivity analysis demonstrated differential responses to therapeutic agents between high and low DAPK1+ macrophage risk score groups, suggesting potential implications for personalized treatment strategies targeting DAPK1-associated pathways in GBM (73, 74). Here, DAPK1 is linked to glioblastoma.